维生素D、钙或联合补充用于社区居住成人骨折一级预防:美国预防服务工作组证据报告与系统评价
该系统评价纳入11项随机对照试验(N=51 419),对象为50岁及以上社区居住成人,干预为补充维生素D、钙或两者联合,随访2至7年。与安慰剂相比,单独补充维生素D降低总骨折发生率(1项RCT,n=2686;绝对风险差-2.26%[95%CI,-4.53%至0.00%]),但与髋部骨折无显著关联(3项RCT,n=5496;合并绝对风险差-0.01%[95%CI,-0.80%至0.78%])。维生素D联合钙对总骨折(1项RCT,n=36 282;绝对风险差-0.35%[95%CI,-1.02%至0.31%])或髋部骨折(2项RCT,n=36 727;较大试验的绝对风险差-0.14%[95%CI,-0.34%至0.07%])均无影响。维生素D联合钙与肾结石发生率增加相关(3项RCT,n=39 213;合并绝对风险差0.33%[95%CI,0.06%至0.60%])。
要点
- 在无已知维生素D缺乏、骨质疏松或既往骨折的社区居住50岁及以上成人中,维生素D联合钙对总骨折(ARD -0.35%[95%CI,-1.02%至0.31%])和髋部骨折(ARD -0.14%[95%CI,-0.34%至0.07%])均无显著影响。
- 单独补充维生素D与总骨折发生率降低相关(1项RCT,n=2686;ARD -2.26%[95%CI,-4.53%至0.00%]),但与髋部骨折无显著关联(3项RCT,n=5496;合并ARD -0.01%[95%CI,-0.80%至0.78%])。
- 维生素D联合钙与肾结石发生率增加相关(3项RCT,n=39 213;合并ARD 0.33%[95%CI,0.06%至0.60%]),而单独补钙未显示肾结石风险增加(3项RCT,n=1259;合并ARD 0.00%[95%CI,-0.87%至0.87%])。
- 维生素D单独或联合钙对全因死亡率或心血管疾病发生率均无显著影响,绝对风险差范围为-1.93%至1.79%,置信区间与无显著差异一致。
- 单独补钙的证据有限,仅2项研究(n=339)且结果极不精确。
适用人群与场景
- 社区居住的50岁及以上成人。
- 排除机构化人群以及已知维生素D缺乏、骨质疏松或既往骨折的人群。
研究设计与关键结果
- 研究设计:系统评价与荟萃分析,纳入11项随机对照试验(N=51 419),对象为50岁及以上成人,随访2至7年。
- 主要终点:与安慰剂相比,单独补充维生素D降低总骨折发生率(1项RCT,n=2686;绝对风险差-2.26%[95%CI,-4.53%至0.00%]),但与髋部骨折无显著关联(3项RCT,n=5496;合并绝对风险差-0.01%[95%CI,-0.80%至0.78%])。
- 维生素D联合钙对总骨折发生率无影响(1项RCT,n=36 282;绝对风险差-0.35%[95%CI,-1.02%至0.31%]),对髋部骨折发生率亦无影响(2项RCT,n=36 727;较大试验的绝对风险差-0.14%[95%CI,-0.34%至0.07%])。
- 单独补钙的证据有限,仅2项研究(n=339),结果极不精确。
- 维生素D单独或联合钙对全因死亡率或新发心血管疾病均无显著影响,绝对风险差范围为-1.93%至1.79%,置信区间与无显著差异一致。
- 维生素D联合钙与肾结石发生率增加相关(3项RCT,n=39 213;合并绝对风险差0.33%[95%CI,0.06%至0.60%]),单独补钙未显示肾结石风险增加(3项RCT,n=1259;合并绝对风险差0.00%[95%CI,-0.87%至0.87%])。
- 维生素D联合钙与癌症发生率增加无关(3项RCT,n=39 213;合并绝对风险差-1.48%[95%CI,-3.32%至0.35%])。
证据类型、等级与局限
- 证据类型:针对美国预防服务工作组的系统评价与荟萃分析,纳入11项随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在无已知维生素D缺乏、骨质疏松或既往骨折的社区居住50岁及以上成人中,单独补充维生素D或联合钙均未显示降低骨折发生率,临床决策时应结合此证据。
- 对于考虑维生素D联合钙补充的社区居住成人,需注意肾结石发生率增加的相关性(合并绝对风险差0.33%[95%CI,0.06%至0.60%])。
指南或共识出处
- 美国预防服务工作组证据报告与系统评价
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Osteoporotic fractures result in significant morbidity and mortality.
OBJECTIVE: To update the evidence for benefits and harms of vitamin D, calcium, or combined supplementation for the primary prevention of fractures in community-dwelling adults to inform the US Preventive Services Task Force.
DATA SOURCES: PubMed, EMBASE, Cochrane Library, and trial registries through March 21, 2017; references; and experts. Surveillance continued through February 28, 2018.
STUDY SELECTION: English-language randomized clinical trials (RCTs) or observational studies of supplementation with vitamin D, calcium, or both among adult populations; studies of populations that were institutionalized or had known vitamin D deficiency, osteoporosis, or prior fracture were excluded.
DATA EXTRACTION AND SYNTHESIS: Dual, independent review of titles/abstracts and full-text articles and study quality rating using predefined criteria. Random-effects meta-analysis used when at least 3 similar studies were available.
MAIN OUTCOMES AND MEASURES: Incident fracture, mortality, kidney stones, cardiovascular events, and cancer.
RESULTS: Eleven RCTs (N = 51 419) in adults 50 years and older conducted over 2 to 7 years were included. Compared with placebo, supplementation with vitamin D decreased total fracture incidence (1 RCT [n = 2686]; absolute risk difference [ARD], -2.26% [95% CI, -4.53% to 0.00%]) but had no significant association with hip fracture (3 RCTs [n = 5496]; pooled ARD, -0.01% [95% CI, -0.80% to 0.78%]). Supplementation using vitamin D with calcium had no effect on total fracture incidence (1 RCT [n = 36 282]; ARD, -0.35% [95% CI, -1.02% to 0.31%]) or hip fracture incidence (2 RCTs [n = 36 727]; ARD from the larger trial, -0.14% [95% CI, -0.34% to 0.07%]). The evidence for calcium alone was limited, with only 2 studies (n = 339 total) and very imprecise results. Supplementation with vitamin D alone or with calcium had no significant effect on all-cause mortality or incident cardiovascular disease; ARDs ranged from -1.93% to 1.79%, with CIs consistent with no significant differences. Supplementation using vitamin D with calcium was associated with an increased incidence of kidney stones (3 RCTs [n = 39 213]; pooled ARD, 0.33% [95% CI, 0.06% to 0.60%]), but supplementation with calcium alone was not associated with an increased risk (3 RCTs [n = 1259]; pooled ARD, 0.00% [95% CI, -0.87% to 0.87%]). Supplementation with vitamin D and calcium was not associated with an increase in cancer incidence (3 RCTs [n = 39 213]; pooled ARD, -1.48% [95% CI, -3.32% to 0.35%]).
CONCLUSIONS AND RELEVANCE: Vitamin D supplementation alone or with calcium was not associated with reduced fracture incidence among community-dwelling adults without known vitamin D deficiency, osteoporosis, or prior fracture. Vitamin D with calcium was associated with an increase in the incidence of kidney stones.
参考来源
- Kahwati LC, Weber RP, Pan H, et al. Vitamin D, Calcium, or Combined Supplementation for the Primary Prevention of Fractures in Community-Dwelling Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2018. PMID: 29677308. doi:10.1001/jama.2017.21640
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。